mbt shoes uk -10. 2 Tekmira 147

keen62sail · Wysłany: Nie 18:24, 20 Mar 2011 Temat postu: mbt shoes uk -10. 2 Tekmira 147

Rna Interference Markets --- Aarkstore Enterprise
Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this Publications report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U. S., and analyzes the factors that influence market size and growth for RNAi testing. The main objectives of this study are to: 1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment; 2) obtain a complete understanding of the individual RNAi-testing platforms-from basic principles to clinical applications; 3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets; 4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts; and 5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.
Table of Contents:
1 Overview 7
1. 1 Objectives 7
1. 2 Scope 7
1. 3 Methodology 9
1. 4 Executive Summary 10
2 RNA Interference (RNAi) 13
2. 1 Introduction 13
2. 2 Overview of RNA Interference 13
2. 2. 1 Classes of Endogenous Small RNAs: siRNA, rasiRNA and miRNA 14
2. 2. 2 Mechanism of RNAi In Vivo 15
2. 3 Glossary 18
2. 4 What Areas of Research Does RNAi Impact? 19
2. 4. 1 RNAi Technology in Life Sciences Research, Drug Discovery and Development 20
2. 4. 2 RNAi Technology in Agriculture 26
3 Technology Trends in RNAi Space 29
3. 1 Overview 29
3. 2 End-User Segmentation 29
3. 3 Technologies for Inducing RNAi 30
3. 3. 1 Methods for Detecting Gene Silencing 31
3. 3. 2 Comparison of Strategies for Target Validation 32
3. 3. 3 Libraries of siRNAs/shRNAs to Knock Down Genes En Masse 32
3. 4 miRNA-Based RNAi: The Leading Edge of RNAi Space 38
3. 4. 1 Biological Function of miRNAs 39
3. 4. 2 Role of miRNAs in Disease 40
3. 4. 3 miRNA-based Diagnostics 44
3. 4. 4 miRNA-based Therapeutics 46
3. 5 Market Shifts in RNAi Space: Where Is It Headed? 47
3. 5. 1 Intellectual Property and Patent Issues 48
3. 5. 2 Patents Covering the Molecular Characteristics of the RNAi Agent 48
3. 5. 3 Funding in RNAi Space: Grants, Venture Capital and IPOs 50
3. 5. 4 Partnerships, Alliances, Mergers and Acquisitions 51
3. 6 SWOT Analysis of Technologies and Vendors in RNAi Space 53
4 RNAi Market Analysis 56
4. 1 Overview 56
4. 2 Market Data Collection and Respondent Pool 56
4. 2. 1 Respondent Pool Characteristics 56
4. 3 RNAi Technologies / Products in Research Applications 58
4. 4 RNAi Technologies/Products: Market Shares (Quantitative) 59
4. 5 Quantitative Metrics of RNAi Usage: Market Opportunity and Growth 62
4. 5. 1 Growth of Various Segments in RNAi Space 64
4. 5. 2 Product Formats and Representation in RNAi Marketplace 65
4. 6 RNAi Marketplace: Challenges, Unmet Needs and Drivers 71
4. 6. 1 Unmet Needs in RNAi Space 72
4. 6. 2 RNAi Market: Qualitative Growth Drivers 74
5 The RNAi Landscape 75
5. 1 Overview 75
5. 2 Market Segmentation of RNAi and Segment Characteristics 75
5. 3 Quantitative Market Opportunities in RNAi Space 77
5. 3. 1 Opportunities in miRNA Space 77
5. 3. 2 Opportunities in siRNA/shRNA Space 79
5. 4 RNAi Product Offerings and Associated Business Models 80
5. 5 Challenges for RNAi Therapeutic Development 82
6 RNAi-Based Therapeutics: The Emerging Industry Landscape 84
6. 1 Factors Contributing to the Success of RNAi Therapeutics 84
6. 2 Advantages and Disadvantages of siRNA-based Drugs 85
6. 3 Opportunities and Challenges with RNAi-based Therapeutics 85
6. 4 The Gene Therapy Precedent 86
6. 5 The Antisense Precedent 87
6. 6 Interferon Response 87
6. 7 Delivery of RNAi-based Therapeutics 88
6. 8 Off-Target Effects 90
6. 9 Overwhelming the Endogenous RNAi System-Affecting the microRNA Pathway 90
6. 10 RNAi-based Therapeutics 90
6. 10. 1 Cancer 91
6. 10. 2 Cardiac Disease 93
6. 10. 3 Immunologic Disease 94
6. 10. 4 Infectious Disease 94
6. 10. 5 Inflammation 97
6. 10. 6 Lifestyle Therapeutics 97
6. 10. 7 Metabolic Disease 97
6. 10. 8 Neurologic Disease 98
6. 10. 9 Ophthalmic Disease 98
6. 10. 10 Renal Disease 100
6. 10. 11 Respiratory Disease 100
7 Company Profiles-U. S. 101
7. 1 Alfacell Corporation 102
7. 2 Allele Biotechnology and Pharmaceuticals, Inc. 102
7. 3 Alnylam Pharmaceuticals 102
7. 4 Ambion 104
7. 5 Asuragen, Inc. 105
7. 6 Avalon Pharmaceuticals, Inc. 105
7. 7 B-Bridge International,[link widoczny dla zalogowanych], Inc. 106
7. 8 Bio-Rad Laboratories 106
7. 9 Calando Pharmaceuticals,[link widoczny dla zalogowanych], Inc. 107
7. 10 Cepheid 107
7. 11 Cequent 107
7. 12 Clontech Laboratories, Inc. 108
7. 13 CombiMatrix Corporation 108
7. 14 Cyntellect, Inc. 108
7. 15 CytRx Corp. 109
7. 16 Dharmacon 110
7. 17 Dicerna 110
7. 18 Galenea Corporation 110
7. 19 GeneCopoeia, Inc. 111
7. 20 GeneThera, Inc. 111
7. 21 Genlantis 111
7. 22 GenoSensor 111
7. 23 GRL, Inc. 112
7. 24 IDT 112
7. 25 Imgenex Corporation 112
7. 26 Ingenuity Systems 113
7. 27 Intradigm Corporation 113
7. 28 Invitrogen 113
7. 29 InvivoGen 114
7. 30 Isis Pharmaceuticals, LLC 114
7. 31 LC Sciences 115
7. 32 Lentigen Corporation 116
7. 33 Merck & Co., Inc. 116
7. 34 Mirus Bio Corporation (Acquired by Roche) 116
7. 35 Monsanto 116
7. 36 Nastech Pharmaceutical Company, Inc. 117
7. 37 New England BioLabs 118
7. 38 Nucleonics,[link widoczny dla zalogowanych], Inc. 118
7. 39 Open Biosystems, Inc. 119
7. 40 OPKO Health, Inc. 119
7. 41 OriGene 120
7. 42 Panomics, Inc. 120
7. 43 PhaseRx 120
7. 44 Promega Corp. 120
7. 45 Quark Pharmaceuticals, Inc. 121
7. 46 RXi Pharmaceuticals Corporation 121
7. 47 Senetek PLC 122
7. 48 Sigma-Aldrich 122
7. 49 Sirna Therapeutics 123
7. 50 Sirnaomics, Inc. 124
7. 51 SomaGenics, Inc. 125
7. 52 System Biosciences 125
7. 53 Tacere Therapeutics 125
7. 54 Targeted Genetics Corporation 126
7. 55 Third Wave Technologies 126
7. 56 Traversa 126
8 Company Profiles-Europe 128
8. 1 Actigenics SA 128
8. 2 Amaxa 128
8. 3 AstraZeneca PLC 129
8. 4 Cenix Bioscience GmbH 129
8. 5 deVGen N. V. 130
8. 6 DNAVision 130
8. 7 Exiqon 131
8. 8 Genovis 131
8. 9 genOway 131
8. 10 imaGenes GmbH 132
8. 11 MWG Biotech AG 132
8. 12 OZ Biosciences 132
8. 13 Prosensa Holding 133
8. 14 QIAGEN 133
8. 15 RNAx GmbH (Germany) 134
8. 16 Roche 135
8. 17 Rosetta Genomics,[link widoczny dla zalogowanych], Ltd. 136
8. 18 Santaris Pharma A/S 136
8. 19 Silence Therapeutics PLC 137
8. 20 TaconicArtemis GmbH 138
8. 21 TRANSAT 138
9 Company Profiles-Asia-Pacific 140
9. 1 alphaGEN Co., Ltd. 140
9. 2 Benitec, Ltd. 140
9. 3 Bioneer 140
9. 4 CytoPathfinder, Inc. 141
9. 5 Genesis Research & Development Corp. 141
9. 6 GeneDesign, Inc. 142
9. 7 GNI Pharmaceutical Corporation 142
9. 8 Koken Co., Ltd. 142
9. 9 NanoCarrier Co., Ltd. 142
9. 10 Oncolys Biopharma, Inc. 143
9. 11 RealGene Bio-Technologies, Inc. 143
9. 12 Samchully Pharmaceuticals 143
9. 13 Samyang Corp. 143
9. 14 Shanghai Biochip 144
9. 15 Shanghai GenePharma Co. 144
9. 16 Shanghai Genomics, Inc. 144
9. 17 Transgene Biotek, Ltd. 145
10 Company Profiles-Rest of the World 146
10. 1 Benitec, Ltd. 146
10. 2 Tekmira 147
INDEX OF TABLES
Table 2. 1: Advantages/Disadvantages of siRNAs and shRNAs as Inducers of RNAi in Mammalian Cells 20
Table 2. 2: Prevalence of siRNA-mediated RNAi in Disease Models, as Reported in Scientific Literature 22
Table 2. 3: RNAi-based Therapeutics in Clinical Trials 23
Table 2. 4: Suppliers of Enabling Technologies and Tools in RNAi Space 24
Table 2. 5: Suppliers of siRNA/shRNA Products (by Product/Service Class) 25
Table 3. 1: Currently-Utilized Technologies for Inducing RNAi-Mediated Knockdown 31
Table 3. 2: Comparison of mRNA Detection Technologies 31
Table 3. 3: Strategies for Target Validation by Pharma/Biotech: RNAi and Others 32
Table 3. 4: Comparison of Formats for Library-Based Gene Knockdown 34
Table 3. 5: Characteristics of Various Publicly-Available Mouse and Human RNAi Libraries 35
Table 3. 6: Disease-Related miRNAs 44
Table 3. 7: Publicly-Available Computational Programs for Identifying miRNA Sequences/Targets 45
Table 3. 8: Seminal Patents in RNAi 49
Table 3. 9: Venture Capital Raised by Selected C
For more information, please visit: http: //www. aarkstore. com/reports/RNA-Interference-Markets-1195. html
Contact: Sanaa
Aarkstore Enterprise
Tel: +912227453309
Mobile No: +919272852585
Email: contact@aarkstore. com
相关的主题文章：

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]